Investors purchased shares of Bristol-Myers Squibb Co (NYSE:BMY) on weakness during trading on Wednesday. $112.49 million flowed into the stock on the tick-up and $49.16 million flowed out of the stock on the tick-down, for a money net flow of $63.33 million into the stock. Of all stocks tracked, Bristol-Myers Squibb had the 15th highest net in-flow for the day. Bristol-Myers Squibb traded down ($0.16) for the day and closed at $60.33

A number of equities research analysts have issued reports on BMY shares. Credit Suisse Group reissued a “hold” rating on shares of Bristol-Myers Squibb in a research note on Wednesday. Atlantic Securities raised shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 target price for the company in a research note on Wednesday, August 8th. SunTrust Banks reissued a “buy” rating and set a $67.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, July 31st. BMO Capital Markets lifted their target price on shares of Bristol-Myers Squibb from $47.00 to $51.00 and gave the company a “market perform” rating in a research note on Monday, July 23rd. Finally, Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Sunday, July 15th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $63.01.

The company has a market cap of $100.21 billion, a PE ratio of 20.04, a price-to-earnings-growth ratio of 1.55 and a beta of 1.02. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.28 and a current ratio of 1.40.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The business had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.48 billion. During the same quarter in the previous year, the business earned $0.74 EPS. Bristol-Myers Squibb’s quarterly revenue was up 10.9% compared to the same quarter last year. equities research analysts anticipate that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Investors of record on Friday, October 5th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.65%. Bristol-Myers Squibb’s payout ratio is presently 53.16%.

Several hedge funds have recently added to or reduced their stakes in the stock. Signature Financial Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 1.9% in the 2nd quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock valued at $2,546,000 after purchasing an additional 870 shares during the last quarter. DnB Asset Management AS lifted its stake in shares of Bristol-Myers Squibb by 0.3% in the 2nd quarter. DnB Asset Management AS now owns 321,762 shares of the biopharmaceutical company’s stock valued at $17,806,000 after purchasing an additional 900 shares during the last quarter. Mcmillion Capital Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 1.4% in the 2nd quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock valued at $3,544,000 after purchasing an additional 903 shares during the last quarter. Securian Asset Management Inc lifted its stake in shares of Bristol-Myers Squibb by 0.5% in the 2nd quarter. Securian Asset Management Inc now owns 167,108 shares of the biopharmaceutical company’s stock valued at $9,248,000 after purchasing an additional 912 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Bristol-Myers Squibb by 4.9% in the 2nd quarter. Itau Unibanco Holding S.A. now owns 19,840 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 926 shares during the last quarter. 72.29% of the stock is owned by institutional investors and hedge funds.

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.